In line with the Cadila Healthcare’s annual report for fiscal 12 months 2019-20, the corporate is planning to introduce extra “topical, transdermal and injectable merchandise” in coming years.
The US was the most important contributor to the consolidated revenues of the corporate with 45 per cent share, the report mentioned.
“Going ahead, the US generics enterprise is more likely to proceed its development momentum on the again of recent product launches and enlargement of general product choices as the corporate is planning to introduce extra topical, transdermal and injectable merchandise in coming years,” it added.
The corporate launched 30 new merchandise within the US generics market. New launches included Rivastigmine Transdermal Patch, which is the primary transdermal patch launched from the corporate’s personal pipeline, the report mentioned.
By way of abbreviated new drug software (ANDA) filings, 30 extra ANDAs had been filed with america Meals and Drug Administration (USFDA) through the 12 months, taking the cumulative variety of ANDA filings to 390.
The corporate acquired approval for 28 ANDAs through the 12 months (together with 5 tentative approvals). Cumulative variety of ANDA approvals on the finish of the 12 months stood at 282, it added.
The corporate will proceed to have a look at the alternatives to increase its presence within the specialty house by way of extra merchandise within the ache administration therapeutic space and enlargement into different centered remedy areas, it mentioned.